186 related articles for article (PubMed ID: 2411968)
1. [Clinicopathological study of latent carcinoma--with special reference to prostatic cancer].
Moriwaki S; Yamamoto Y; Takashima S; Uyama K; Higa I; Kanayama H
Gan No Rinsho; 1985 Jun; 31(7):847-53. PubMed ID: 2411968
[TBL] [Abstract][Full Text] [Related]
2. [Tumor markers of prostate cancer--evaluation of serum PAP and PA].
Miki M
Gan No Rinsho; 1985 May; 31(6 Suppl):664-9. PubMed ID: 2411965
[TBL] [Abstract][Full Text] [Related]
3. [Anatomoclinical and biologic correlations in prostatic pathology. Apropos of 150 case reports].
Amiel J; Chevallier D; Peyrottes A; Benoliel J; Toubol J
Ann Urol (Paris); 1989; 23(6):528-30. PubMed ID: 2482700
[TBL] [Abstract][Full Text] [Related]
4. Prostatic acid phosphatase and prostate-specific antigen in prostate cancer.
Kuriyama M; Loor R; Wang MC; Lee C; Killian CS; Papsidero LD; Inaji H; Nishiura T; Slack NH; Murphy GP; Chu TM
Int Adv Surg Oncol; 1982; 5():29-49. PubMed ID: 6178696
[No Abstract] [Full Text] [Related]
5. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
6. [Prostate-specific antigen. A new marker of prostatic pathology].
Boccon-Gibod L; Géraud M; Dugué MA
Ann Urol (Paris); 1988; 22(3):206-10. PubMed ID: 2456714
[TBL] [Abstract][Full Text] [Related]
7. [Prostatic carcinoma: immunoperoxidase study with antisera against prostatic acid phosphatase and the prostate-specific antigen].
Mathieu MC; Caillaud JM
Bull Cancer; 1985; 72(5):405-13. PubMed ID: 2416371
[TBL] [Abstract][Full Text] [Related]
8. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
Morote Robles J; de Torres Mateos JA
Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148
[TBL] [Abstract][Full Text] [Related]
9. [The value of the serum level of the prostate-specific antigen in prostatic pathology].
Théodon P; Rymer JC; Chopin D; Kouyoudjian JC; Abbou CC; Auvert J
Ann Urol (Paris); 1988; 22(3):199-205. PubMed ID: 2456713
[TBL] [Abstract][Full Text] [Related]
10. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.
Purnell DM; Heatfield BM; Trump BF
Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163
[TBL] [Abstract][Full Text] [Related]
11. [Clinical relevance of radioimmunologic determination of prostate specific antigen in prostate cancer].
Fornara P; Sturm W; Fabricius PG; Schmiedt E
Urologe A; 1987 May; 26(3):158-61. PubMed ID: 2440170
[TBL] [Abstract][Full Text] [Related]
12. Incidence of impalpable carcinoma of the prostate and of non-malignant and precarcinomatous lesions in Greek male population: an autopsy study.
Stamatiou K; Alevizos A; Agapitos E; Sofras F
Prostate; 2006 Sep; 66(12):1319-28. PubMed ID: 16688747
[TBL] [Abstract][Full Text] [Related]
13. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens.
Kuriyama M; Wang MC; Lee CL; Killian CS; Papsidero LD; Inaji H; Loor RM; Lin MF; Nishiura T; Slack NH; Murphy GP; Chu TM
J Natl Cancer Inst; 1982 Jan; 68(1):99-105. PubMed ID: 6172628
[TBL] [Abstract][Full Text] [Related]
14. [Role of prostate-specific antigen in prostatic carcinoma. Validity of an integrated methodologic approach and morpho-biological correlations].
Tomasino RM; Lo Bianco A; Cacciatore M; Pavone C; Carreca I; Morello V; Salvato M; Florena AM; Pavone-Macaluso M
Pathologica; 1989; 81(1072):109-26. PubMed ID: 2475847
[TBL] [Abstract][Full Text] [Related]
15. Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level.
Punglia RS; D'Amico AV; Catalona WJ; Roehl KA; Kuntz KM
Cancer; 2006 Apr; 106(7):1507-13. PubMed ID: 16518812
[TBL] [Abstract][Full Text] [Related]
16. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
Tarle M; Kraljić I
Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
[TBL] [Abstract][Full Text] [Related]
17. [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer].
Akimoto S; Akakura K; Shimazaki J
Hinyokika Kiyo; 1988 Aug; 34(8):1389-96. PubMed ID: 2461644
[TBL] [Abstract][Full Text] [Related]
18. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
[TBL] [Abstract][Full Text] [Related]
19. The role of prostate-specific antigen in the chemoprevention of prostate cancer.
Crawford ED; DeAntoni EP; Ross CA
J Cell Biochem Suppl; 1996; 25():149-55. PubMed ID: 9027612
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens.
Pacelli A; Bostwick DG
Urology; 1997 Sep; 50(3):355-9. PubMed ID: 9301697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
